multicenter study to prove that co-administration of gemcitabine, erlotinib and Hyangsayukgunja-tang extracts is improved the quality of life including pain and anorexia in patients with pancreatic cancer.
- Conditions
- Not Applicable
- Registration Number
- KCT0001407
- Lead Sponsor
- Daegu Catholic Univercity Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 38
Selection Criteria (meeting all of the following conditions)
1. Admitted or outpatient pancreatic cancer patient who is currently on or scheduled for gemcitabine, erlotinib treatment.
2. Patient with ECOG performance 2 or less
3. Age over 20yrs old and under 80yrs old
4. No damage to cognitive ability
5. Self determined participation with written consent signed by the patient or legal guardian.
6. Patient who can be followed during the trial period
Exclusion Criteria(satisfy any one of the following conditions)
1. Pancreatic cancer patient who is scheduled to have a surgical treatment after chemotherapy
2. patient with gastrointestinal obstruction requiring surgical treatment.
3. Hypertensive patient whose blood pressure is not controlled well with medication.
4. Hepatic or renal function test value exceeding 3times that of normal limit or AST, ALT over 200IU/L, Creatinine 3.4mg/dl or higher.
5. Patient with severe edema.
6. Failure of patient to give a written consent.
7. Patient who is determined unfit for this study due to poor physical or mental status by study conductor.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain rating scale;Quality of Life (EORTC QLQ-C30)
- Secondary Outcome Measures
Name Time Method ghrelin, obstatin;survival, adverse events of chemotherapy (nausea/vomiting, thrombocytopenia, skin rash)